181 related articles for article (PubMed ID: 37174688)
1. ATM Inhibition-Induced ISG15/IFI27/OASL Is Correlated with Immunotherapy Response and Inflamed Immunophenotype.
Huang CH; Huang YC; Xu JK; Chen SY; Tseng LC; Huang JL; Lin CS
Cells; 2023 Apr; 12(9):. PubMed ID: 37174688
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.
Zhang Q; Green MD; Lang X; Lazarus J; Parsels JD; Wei S; Parsels LA; Shi J; Ramnath N; Wahl DR; Pasca di Magliano M; Frankel TL; Kryczek I; Lei YL; Lawrence TS; Zou W; Morgan MA
Cancer Res; 2019 Aug; 79(15):3940-3951. PubMed ID: 31101760
[TBL] [Abstract][Full Text] [Related]
3. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.
Hu M; Zhou M; Bao X; Pan D; Jiao M; Liu X; Li F; Li CY
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33290271
[TBL] [Abstract][Full Text] [Related]
4. Liposomal ATM siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy.
Yu D; Wang H; Liu H; Xu R
J Biomater Appl; 2023 May; 37(10):1835-1846. PubMed ID: 37016537
[TBL] [Abstract][Full Text] [Related]
5. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
[TBL] [Abstract][Full Text] [Related]
6. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D
J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors.
Wang L; Yang L; Wang C; Zhao W; Ju Z; Zhang W; Shen J; Peng Y; An C; Luu YT; Song S; Yap TA; Ajani JA; Mills GB; Shen X; Peng G
J Clin Invest; 2020 Nov; 130(11):5951-5966. PubMed ID: 33016929
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the Deregulation of Protein Turnover Pathways in Atm-Deficient Mouse Cerebellum: An Organotypic Study.
Kim CD; Reed RE; Juncker MA; Fang Z; Desai SD
J Neuropathol Exp Neurol; 2017 Jul; 76(7):578-584. PubMed ID: 28535250
[TBL] [Abstract][Full Text] [Related]
9. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
10. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
[TBL] [Abstract][Full Text] [Related]
11. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
12. Ataxia telangiectasia mutated kinase mediates NF-κB serine 276 phosphorylation and interferon expression via the IRF7-RIG-I amplification loop in paramyxovirus infection.
Fang L; Choudhary S; Tian B; Boldogh I; Yang C; Ivanciuc T; Ma Y; Garofalo RP; Brasier AR
J Virol; 2015 Mar; 89(5):2628-42. PubMed ID: 25520509
[TBL] [Abstract][Full Text] [Related]
13. ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.
Sun L; Wang RC; Zhang Q; Guo LL
Pathol Res Pract; 2020 Aug; 216(8):153032. PubMed ID: 32703496
[TBL] [Abstract][Full Text] [Related]
14. Interferon stimulated gene 15 (ISG15) in cancer: An update.
Nguyen HM; Gaikwad S; Oladejo M; Agrawal MY; Srivastava SK; Wood LM
Cancer Lett; 2023 Mar; 556():216080. PubMed ID: 36736853
[TBL] [Abstract][Full Text] [Related]
15. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract][Full Text] [Related]
16. ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.
Burks J; Fleury A; Livingston S; Smith JP
Cancer Immunol Immunother; 2019 Dec; 68(12):2029-2039. PubMed ID: 31709456
[TBL] [Abstract][Full Text] [Related]
17. Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin.
Lv J; Qian Y; Ni X; Xu X; Dong X
Tumour Biol; 2017 Mar; 39(3):1010428317694307. PubMed ID: 28347251
[TBL] [Abstract][Full Text] [Related]
18. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
[TBL] [Abstract][Full Text] [Related]
19. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
